ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0631

Perfluoroalkyl Substances and Community Vulnerability: Associations with Lupus-Related Autoantibodies and Disease

Emily Vara, Dulaney Wilson, John Pearce, Jim Oates and Diane Kamen, Medical University of South Carolina, Charleston, SC

Meeting: ACR Convergence 2022

Keywords: autoantigens, Disparities, Environmental factors, Minority Health, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Perfluoroalkyl substances (PFAS) are a class of persistent organic pollutants found in nonstick products, water repellant fabrics, fire-retardant foams, and food packaging. Highly stable, the compounds persist in soil and water, bioaccumulate, and are found in the blood and tissues of animals and humans. Several PFAS, including perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS), have been associated with negative health effects through hormone disruption and immunologic dysfunction.

This ongoing study explores the associations between PFAS biomarkers, autoimmunity, and neighborhood-level social determinants of health among African Americans participating in a population-based cohort study.

Methods: Data was utilized from a longitudinal study of Gullah African American patients with SLE and non-SLE controls. Demographics, medical history, Social Vulnerability Index (SVI) (incorporating socioeconomic status, household composition, race/ethnicity/language, and housing/transportation), antinuclear antibody (ANA) status and titer, serum PFOA concentration (ng/mL), and serum PFOS concentration (ng/ml) from in-person visits from 2003-2019 were included. Spatial overlays were applied to assign census tract identifiers and obtain SVI data for the participants. Statistical analysis using univariate and multivariate linear regression was performed.

Results: A total of 81 participants, including 10 patients with SLE and 71 non-SLE controls were evaluated. All were non-Hispanic black, 85% female and 15% male (Table 1). In the linear regression modeling, participants with PFOS exposure had a small increase (worsening) in SVI for every one unit increase in the serum PFOS concentration (median PFOS concentration 24.7 ng/mL) (0.30; 95% CI=0.04,0.60). SVI was not significantly associated with PFOA exposure (median PFOA concentration 3.6 ng/mL), (1.38; 95% CI=-1.63,4.39). Participants with a positive ANA had a statistically significant increase in mean SVI (16.1; 95% CI 3.17, 29.07) compared to those with a negative ANA. There was no significant difference in SVI between patients with SLE and controls (-7.1; 95% CI= -26.9,12.75), by age (0.05; 95% CI=-0.4, 0.49) or gender (-5.49; 95% CI=-25.6, 13.6). Adjusting for positive ANA, the association between PFOS exposure and SVI remained significant, albeit small, (0.3; 95% CI=0.17, 0.59) and there remained no significant association between SVI and PFOA (1.84; 95% CI= -1.09, 4.76) (Table 2).

Conclusion: In our study of African Americans with and without SLE, PFOS, but not PFOA, exposure was associated with higher social vulnerability measured by the SVI after adjustment for ANA positivity. SLE diagnosis was not associated with higher social vulnerability, possibly due to the small number of participants with SLE. These findings support continued studies of PFAS and other environmental contaminants which are associated with disparities in exposure, putting vulnerable communities at risk for adverse health impacts such as SLE.

Supporting image 1

Table 1. Demographics, serology, and toxiciology levels of participants.

Supporting image 2

Table 2. Univariate and multivariate linear regression analysis.

Supporting image 3

Figure 1. Box and whisker plots showing (a) PFOS by gender and ANA positivity for controls, (b) PFOA by gender and ANA positivity for controls, and (c) SVI by gender and ANA positivity for controls.


Disclosures: E. Vara, None; D. Wilson, None; J. Pearce, None; J. Oates, None; D. Kamen, None.

To cite this abstract in AMA style:

Vara E, Wilson D, Pearce J, Oates J, Kamen D. Perfluoroalkyl Substances and Community Vulnerability: Associations with Lupus-Related Autoantibodies and Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/perfluoroalkyl-substances-and-community-vulnerability-associations-with-lupus-related-autoantibodies-and-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/perfluoroalkyl-substances-and-community-vulnerability-associations-with-lupus-related-autoantibodies-and-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology